| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3264 | Mc-doxhzn | Albumin-binding prodrug of Doxorubicin |
|
| DCC3265 | Mcg315 | Novel potent F508del-CFTR corrector, modulating poly-ADP ribose polymerase 3 and poly-ADP ribose polymerase 16 activities |
|
| DCC3266 | Mci-225 | Selective NA reuptake inhibitor with 5-HT3 receptor antagonism |
|
| DCC3267 | Mcl0527-3 | Novel inhibitor of p53-MDM2 interaction |
|
| DCC3268 | Mcl-1 Degrader C3 | Novel potent and selective degrader of Mcl-1 |
|
| DCC3269 | Mcl-1 Inhibitor-11 | Novel reversible covalent inhibitor for Mcl-1 with improved water solubility than Mcl-1 Inhibitor-5 |
|
| DCC3270 | Mcl-1 Inhibitor-39 | Novel selective Mcl-1 inhibitor |
|
| DCC3271 | Mcl-1 Inhibitor-5 | The first reversible covalent inhibitor for Mcl-1, a protein-protein interaction (PPI) target |
|
| DCC3272 | Mcl1-in-1 | Novel potent and selective inhibitor of the apoptosis regulating proteins Mcl-1 |
|
| DCC3273 | Mcmmad Featured | Novel mc (maleimidocaproyl) linker plus MMAD (Monomethylauristatin D) to be used for prepare antibodies conjugates via cysteine-capped mechanism |
|
| DCC3274 | Mct4-in-18n | Novel highly selective inhibitor of monocarboxylate transporter 4 (MCT4/SLC16A3), resulting in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells |
|
| DCC3275 | Mcule-5948770040 | Novel SARS-CoV-2 Main Protease (Mpro) inhibitor, binding to Subsites S1 and S2 (Kd=1.3 µM) |
|
| DCC3276 | Md-222 | First-in-class highly potent PROTAC degrader of MDM2 |
|
| DCC3277 | Md-39-am | Diuretic agent, impling an increase in the Na+ excretion and showing antihypertensive effect |
|
| DCC3278 | Mdc-1112 | Novel valproic acid (VPA) derivative, as a potent STAT3 inhibitor |
|
| DCC3279 | Mdcccl1636 | Novel partial PPARgamma ligand, displaying partial agonist activity in biochemical and cell-based transactivation assays, and reversed insulin resistance |
|
| DCC3280 | Mdctmp | Novel proteolysis-resistant self-localizing ligand (SL), sustaining PM localization of eDHFR-fusion proteins (over several hours to a day), inducing prolonged signal activation and cell differentiation |
|
| DCC3281 | Mde 6-82-1c | Novel MC5R antagonist |
|
| DCC3282 | Mde10-136rs | Novel potent and highly selective melanocortin-3 receptor (MC3R) agonist, showing greater than 140-fold selective for the mMC3R over the mMC4R, possessed 70 nM potency at the mMC3R, and partially stimulated the mMC4R at 100 μM concentrations without antag |
|
| DCC3283 | Mde6-5-2c | Novel potent and nonselective MC3R and MC4R macrocyclic agonist. decreased food intake and respiratory exchange ratio (RER) |
|
| DCC3284 | Mdg486 | Novel Inhibitor of BAF, activating latent HIV-1 |
|
| DCC3285 | mdg559 | Novel peroxisome proliferator activated receptor |
|
| DCC3286 | mdg582 | Novel peroxisome proliferator activated receptor γ (PPARγ) ligand |
|
| DCC3287 | Mdl100240 | Dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase |
|
| DCC3288 | Mdm2/x Pdi | Potent Peptide dual inhibitor of MDM2/X, inhibiting p53 interactions with MDM2 (IC50 = 10 nmol/L) and MDMX (IC50 = 100 nmol/L), inducing apoptosis and cell cycle arrest of cell lines with overexpressed MDM2/X |
|
| DCC3289 | Mdm2/xiap-in-14 | Novel potent dual MDM2/XIAP inhibitor |
|
| DCC3290 | Mdm2-p53-in-1b | Novel inhibitor of the MDM2-p53 interaction |
|
| DCC3291 | Mdmb-chminaca | Potent ligand of the central CB1 receptor |
|
| DCC3292 | Me1111 | Novel selective inhibitor of succinate dehydrogenase (complex II) of dermatophyte species |
|
| DCC3293 | me6tren Tetrahydrochloride | Potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs), activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD3100 |
|
